Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
Jaguar Health, Inc. filed a Form 8-K reporting events occurring on September 23, 2026, with the report signed on September 24, 2026. The company is a Delaware corporation headquartered in San Francisco, California, and its common stock trades on Nasdaq under the symbol JAGX.
Material Financing Transaction
- The company entered into privately negotiated exchange agreements with Streeterville Capital, LLC, the holder of the company’s secured 2025 promissory note.
- Jaguar issued 547,898 shares of common stock to Streeterville in exchange for a $5,049,909.26 reduction in the outstanding balance of the 2025 Note.
- The 2025 Note was originally issued on November 12, 2025, with principal of $10,810,000.
- The shares were issued without registration under Section 3(a)(9) of the Securities Act.
- As of September 23, 2026, approximately 1,281,867 shares of common stock were issued and outstanding. The exchange shares represented approximately 42.7% of that reported share count, before considering any other issuances or adjustments.
Financial Metrics and Liquidity
- The transaction reduced the company’s outstanding debt balance by $5,049,909.26.
- The filing does not provide revenue, net income, cash flow, operating margins, cash balances, liquidity runway, interest expense, or the remaining balance of the 2025 Note after the exchange.
- The filing does not state whether the transaction generated cash proceeds; the disclosed consideration was an equity-for-debt exchange.
Changes Versus the Prior Comparable Period
Relative to the previously disclosed 2025 Note, the company reduced its outstanding balance by approximately $5.05 million and issued 547,898 shares to the noteholder. The filing does not provide prior-period operating results or a comparable-period financial statement.
Outlook, Risks, and Unusual Items
- No financial guidance, operating outlook, or management forecast is provided.
- The principal unusual item is the substantial issuance of common stock in exchange for debt reduction, which may materially dilute existing shareholders.
- The exchange agreements contain customary representations, warranties, and covenants. The filing does not provide the complete economic terms of the agreements beyond the disclosed share issuance and debt reduction.
Important Facts to Verify
- Review Exhibit 10.1 for the complete exchange agreement terms, including any covenants, restrictions, defaults, and settlement provisions.
- Verify the outstanding balance of the 2025 Note after the $5,049,909.26 reduction.
- Reconcile the reported 1,281,867 shares outstanding with the 547,898 newly issued shares and assess resulting ownership concentration and dilution.
- Confirm the accounting treatment and any gain, loss, or debt extinguishment impact in the company’s subsequent financial statements.
- Assess whether additional debt exchanges, equity issuances, or financing requirements are disclosed in later filings.